OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Mesa on Accrual Considerations in MPN Clinical Trials

August 17th 2020

Ruben A. Mesa, MD, discusses accrual considerations in myeloproliferative neoplasms clinical trials.

Dr. El-Khoueiry on the Frontline Treatment Landscape in HCC

August 17th 2020

Anthony B. El-Khoueiry, MD, discusses the frontline treatment landscape of hepatocellular carcinoma.

Dr. Mirza on the Implications of the NSGO-AVANOVA2/ENGOT-OV24 Trial in Ovarian Cancer

August 17th 2020

Mansoor Raza Mirza, MD, discusses the clinical implications of the final survival analysis of the phase 3 NSGO-AVANOVA2/ENGOT-OV24 trial in recurrent, platinum-sensitive ovarian cancer.

Dr. Yardley on Endocrine Therapy Plus CDK4/6 Inhibitors in Breast Cancer With Visceral Metastases

August 17th 2020

Denise Yardley, MD, discusses the role of endocrine therapy in combination with CDK4/6 inhibitors in patients with hormone receptor–positive, HER2-negative breast cancer and visceral metastases.

Dr. Liu on Cediranib/Olaparib in Recurrent Ovarian Cancer

August 14th 2020

Joyce F. Liu, MD, MPH, discusses the results of cediranib in combination with olaparib in a phase 3 trial in patients with recurrent platinum-sensitive ovarian cancer.

Dr. Choueiri on the Significance of the CCC19 During the COVID-19 Crisis

August 14th 2020

Toni K. Choueiri, MD, discusses the significance of the COVID-19 and Cancer Consortium during the coronavirus disease 2019 pandemic.

Dr. Ghosh on Global Trials With Zanubrutinib in MCL and NHL

August 14th 2020

Nilanjan Ghosh, MD, PhD, discusses global trials examining zanubrutinib in mantle cell lymphoma and non-Hodgkin lymphoma.

Dr. Atlas on the Current Treatment Paradigm in CSCC

August 14th 2020

Jennifer L. Atlas, MD, discusses the current cutaneous squamous cell carcinoma treatment paradigm.

Dr. Woyach on the Role of Small Molecule Inhibitors in CLL

August 14th 2020

Jennifer Woyach, MD, discusses the role of small molecule inhibitors in chronic lymphocytic leukemia.

Dr. Shah on BCMA-Directed CAR T-Cell Therapy Research in R/R Multiple Myeloma

August 14th 2020

Nina Shah, MD, discusses ongoing research with BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma.

Dr. Kim on the Evolving Treatment Landscape of Advanced HCC

August 14th 2020

Richard D. Kim, MD, discusses the evolving treatment landscape of advanced hepatocellular carcinoma.

Dr. Sonpavde on Combining VEGF/PD-1 Inhibitors in Metastatic Urothelial Carcinoma

August 14th 2020

Guru P. Sonpavde, MD, discusses the utility of combining anti-VEGF and anti–PD-1 agents in metastatic urothelial carcinoma.

Dr. O'Regan on Emerging CDK4/6 Combinations in Breast Cancer

August 14th 2020

Ruth O’Regan, MD, discusses emerging CDK4/6 inhibitor combinations in breast cancer.

Dr. Pavlick on the Safety Profile of Cemiplimab in CSCC

August 13th 2020

Anna C. Pavlick, DO, discusses common and uncommon adverse effects with cemiplimab in patients with cutaneous squamous cell carcinoma.

Dr. McKay on the Role of Age and Gender in Advanced RCC Outcomes

August 13th 2020

Rana R. McKay, MD, discusses the role of age and gender in advanced renal cell carcinoma outcomes.

Dr. VanderWalde on Future Research in Rectal Cancer

August 13th 2020

Noam VanderWalde, MD, MS, discusses where future research efforts should focus in rectal cancer.

Dr. Han on the Importance of pCR in Breast Cancer

August 13th 2020

Heather S. Han, MD, discusses the importance of pathologic complete response in breast cancer.

Dr. Milhem on Design of Phase 1b/2 Study With AST-008 in CSCC

August 13th 2020

Mohammed M. Milhem, MBBS, discusses the design of an open-label, multicenter phase 1b/2 dose escalation/expansion study with AST-008 in combination with a PD-1 inhibitor, such as pembrolizumab or cemiplimab, in Merkel cell carcinoma and cutaneous squamous cell carcinoma.

Dr. Matulonis on CPS as a Potential Biomarker in Advanced Recurrent Ovarian Cancer

August 13th 2020

Ursula A. Matulonis, MD, discusses the potential role of combined positive score as a biomarker in advanced recurrent ovarian cancer.

Dr. Somer on the Clinical Implications of Atezolizumab/Bevacizumab Approval in HCC

August 13th 2020

Bradley G. Somer, MD, discusses the clinical implications of the FDA approval of atezolizumab in combination with bevacizumab in unresectable or metastatic hepatocellular carcinoma.